| | | Overview | | | | NovaDigm is developing innovative vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The Company’s founding scientists from the LA BioMed Institute at Harbor-UCLA Medical Center are recognized leaders in the field of infectious disease and the emerging threat of “superbugs.” NovaDigm’s lead product candidates target Candida, a fungal pathogen, and Staphylococcus aureus (S. aureus), including MRSA. Based in North Dakota with additional research activities at LA BioMed, NovaDigm has received funding from Domain Associates, a leading health care venture capital firm, and collaborates with multiple government agencies. | | | | NovaDigm’s efforts are focused on development of our lead Candida-Staphylococcal vaccine, NDV-3, which is scheduled to begin Phase I clinical studies in 2010. The Company intends to bring this vaccine into clinical development and seek partners for manufacturing and commercialization. NovaDigm is assessing additional bacterial and fungal vaccine antigens to expand its product candidate pipeline. | | | | Our facility in Grand Forks, North Dakota encompasses 5300 sq. ft. of laboratory and office space. It is located in the Center of Excellence for Life Sciences & Advanced Technologies building adjacent to the University of North Dakota campus. | | | | Funding | | | | NovaDigm’s initial venture investment came from Domain Associates, who committed $18M in a Series A round that closed in June 2008. The Company has been very successful in attracting government grant funding and currently has over $17M in awarded or pending grants. | | | Domain Associates:
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.5 billion of capital under management, Domain is headquartered in Princeton, New Jersey, with a second office in San Diego, California. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field. http://www.domainvc.com/ | | | U.S. Government Funding:
The National Institutes of Health Division of Microbiology and Infectious Diseases (NIH DMID) has supported basic research on a Candida vaccine for the past ten years through RO1 and CO1 grants to NovaDigm’s scientific founders. This groundbreaking research led to the discovery of the Als3 antigen, which NovaDigm has developed into its NDV-3 vaccine candidate. This vaccine has demonstrated efficacy in reducing mortality in preclinical models of both Candida and S. aureus infections. | | | | In addition, the NIH DMID has partnered with NovaDigm to continue development of the vaccine by providing funding and project management of additional preclinical activities, including the manufacture of vaccine clinical supplies. | | | | Based on the significant need for a vaccine to prevent S. aureus and Candida infections in deployed armed forces and military recruits, the U.S. Army has also awarded funding to NovaDigm in each of the last three years to support additional product development activities, including funds to support planned human clinical trials. | | | | Partners | | | | NovaDigm’s scientific founders are affiliated with the Los Angeles Biomedical Research Foundation (LA BioMed) and the Harbor-UCLA Medical Center. The intellectual property that protects NovaDigm’s technology and products are owned by LA BioMed and are licensed to NovaDigm on an exclusive worldwide basis. NovaDigm continues to benefit from close research collaborations with the scientific founders and their institutions. | | | LA BioMed:
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is one of the largest independent non-profit biomedical research enterprises in California and one of the top 20 in the United States. It is also an exceptional training ground, with a commitment to developing tomorrow’s research leaders, as well as an important provider of public health services to the underserved in their local communities. http://www.labiomed.org/ | | | Harbor- UCLA Medical Center:
Harbor-UCLA Medical Center is a Level 1 Trauma Center with an NIH-funded General Clinical Research Center. The 72-acre facility is composed of the 8-story, 553-bed hospital, and a 52,000 square foot Primary Care and Diagnostic Center . The on-campus Los Angeles Biomedical Research Institute, with an annual research budget over $50 million dollars, provides extensive laboratory and administrative facilities for faculty investigators. All of the approximately 300 full-time faculty as well as some of the more than 450 part-time and voluntary professional staff hold faculty appointments at the UCLA School of Medicine. They devote their time to the clinical care of the patients, research, and teaching at Harbor-UCLA Medical Center. http://www.harboruclamed.com/ | | | | | | |
|
|
